Literature DB >> 31525609

Transforming growth factor-beta profiles correlate with clinical symptoms and parameters of haemostasis and inflammation in a controlled human malaria infection.

Gerdie M de Jong1, Matthew B B McCall2, Willem A Dik3, Rolf T Urbanus4, Linda J Wammes1, Rob Koelewijn1, Robert W Sauerwein5, Annelies Verbon1, Jaap J van Hellemond1, Perry J J van Genderen6.   

Abstract

BACKGROUND: After a controlled human malaria infection (CHMI), presentation of clinical signs and symptoms and host responses is heterogeneous. Transforming growth factor-beta (TGF-β) is the first serum cytokine that changes in malaria-naïve volunteers after CHMI. We studied a possible relation between TGF-β changes, pro-inflammatory cytokines, activation of haemostasis and endothelial cells and clinical symptoms.
METHODS: A panel of cytokines including TGF-β, and markers of activation of haemostasis and endothelial cells were measured in blood samples of 15 volunteers at baseline before CHMI and during CHMI at day of treatment. The change of the parameters on the day of treatment was examined for a significant alteration during infection.
RESULTS: Nine of 15 volunteers showed a significant decrease in TGF-β compared to baseline, with concomitant increased concentrations of D-dimer (p = 0.012), Von Willebrand factor (p = 0.017), IL-6 (p = 0.012) and IFN-γ (0.028) and a significantly decreased platelet count (p = 0.011). In contrast, 6 of 15 volunteers showed sustained or increased TGF-β concentrations without change in the aforementioned parameters. The sustained responders presented with less moderate and severe clinical symptoms than the negative responders (p = 0.036) and had a higher baseline lymphocyte count (p = 0.026). TGF-β concentrations did not correlate with the parasitaemia on day of treatment.
CONCLUSION: Early decreases of serum TGF-β might function a marker for a pro-inflammatory host response and downstream clinical symptoms and pathology during CHMI.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical symptoms; Controlled human malaria infection; Haemostasis; Heterogeneity; TGF-β

Mesh:

Substances:

Year:  2019        PMID: 31525609     DOI: 10.1016/j.cyto.2019.154838

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Functional changes in hemostasis during asexual and sexual parasitemia in a controlled human malaria infection.

Authors:  Shengshi Huang; Wouter van der Heijden; Isaie J Reuling; Jun Wan; Qiuting Yan; Romy M W de Laat-Kremers; Andre J Van der Ven; Philip G de Groot; Matthew McCall; Robert W Sauerwein; Teun Bousema; Mark Roest; Marisa Ninivaggi; Quirijn de Mast; Bas de Laat
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

2.  Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum.

Authors:  Kathryn Milne; Alasdair Ivens; Adam J Reid; J Alexandra Rowe; Philip J Spence; Magda E Lotkowska; Aine O'Toole; Geetha Sankaranarayanan; Diana Munoz Sandoval; Wiebke Nahrendorf; Clement Regnault; Nick J Edwards; Sarah E Silk; Ruth O Payne; Angela M Minassian; Navin Venkatraman; Mandy J Sanders; Adrian Vs Hill; Michael Barrett; Matthew Berriman; Simon J Draper
Journal:  Elife       Date:  2021-03-02       Impact factor: 8.140

3.  Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  Stephen D Woolley; Louise Marquart; John Woodford; Stephan Chalon; Joerg J Moehrle; James S McCarthy; Bridget E Barber
Journal:  Malar J       Date:  2021-12-20       Impact factor: 2.979

Review 4.  Recent Advances in Understanding the Inflammatory Response in Malaria: A Review of the Dual Role of Cytokines.

Authors:  Gabriela Loredana Popa; Mircea Ioan Popa
Journal:  J Immunol Res       Date:  2021-11-08       Impact factor: 4.818

5.  Balancing in a black box: Potential immunomodulatory roles for TGF-β signaling during blood-stage malaria.

Authors:  Lisa L Drewry; John T Harty
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.